Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLEPYN)

• Drug Name: Tetramethylammonium Ion Drug Info
• Synonyms: Tetramethylammonium; TETRAMETHYLAMMONIUM ION; tetramethylazanium; 51-92-3; N,N,N-trimethylmethanaminium; UNII-H0W55235FC; Tetramethylammonium octahydrotriborate; EINECS 235-626-5; CHEMBL46486; Methanaminium, N,N,N-trimethyl-, octahydrotriborate(1-); CHEBI:46020; Methanaminium, N,N,N-trimethyl-; H0W55235FC; Tetramethylammonium pentaiodide; Tetramethyl-Ammonium; Ammonium, (pentaiodide); AC1L1MEF; 19269-48-8; bmse000780; 64-20-0 (bromide); 75-59-2 (hydroxide); 75-57-0 (chloride); 75-58-1 (iodide); 12386-10-6; 373-68-2 (fluoride)

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 6380
  ChEBI ID: CHEBI:46020
  CAS Number: CAS 51-92-3
  TTD Drug ID: DMLEPYN
  VARIDT Drug ID: DR01474

Molecule-Related Drug Atlas

Drug(s) Targeting UDP-glucose 4-epimerase (GALE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nicotinamide-Adenine-Dinucleotide	DM9LRKB	N. A.	N. A.	Investigative	[1]
PSAMMAPLIN A	DM6T0IQ	Discovery agent	N.A.	Investigative	[4]
UDP-glucose	DMLT4JA	Discovery agent	N.A.	Investigative	[1]
Uridine Diphosphate Galactose	DMPA0BJ	Discovery agent	N.A.	Investigative	[5]
Uridine-Diphosphate-N-Acetylgalactosamine	DMXHO6J	N. A.	N. A.	Investigative	[1]
Uridine-Diphosphate-N-Acetylglucosamine	DMEQSTP	Discovery agent	N.A.	Investigative	[6]
Uridine-5'-Diphosphate	DMDQKJB	Discovery agent	N.A.	Investigative	[1]
Phenyl-Uridine-5'-Diphosphate	DM7J0YG	Discovery agent	N.A.	Investigative	[1]
Uridine-5'-Diphosphate-Mannose	DMAYCQU	Discovery agent	N.A.	Investigative	[1]

Drug(s) Transported By Organic cation transporter 1 (SLC22A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[7]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[8]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[9]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[10]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[11]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[12]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[13]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[14]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[15]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[16]

Drug(s) Affected By Cholinesterase (BCHE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[17]
Tacrine	DM51FY6	Alzheimer disease	8A20	Approved	[18]
Galantamine	DMEO794	Alzheimer disease	8A20	Approved	[19]
Rivastigmine	DMG629M	Alzheimer disease	8A20	Approved	[20]
Donepezil	DMIYG7Z	Advanced cancer	2A00-2F9Z	Approved	[21]
Succinylcholine	DM2ET1M	Plasma cell myeloma	2A83.1	Approved	[22]
Ethopropazine	DM0N3L7	Parkinson disease	8A00.0	Approved	[18]
Dimenhydrinate	DM264B3	Meniere disease	AB31.0	Approved	[23]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[24]
Chlorpheniramine	DM5URA2	Allergic rhinitis	CA08.0	Approved	[23]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
UDP-glucose 4-epimerase (GALE)	TTGRHIB	GALE_HUMAN	Inhibitor	[1]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic cation transporter 1 (SLC22A1)	DTT79CX	S22A1_HUMAN	Substrate	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cholinesterase (BCHE)	OTOH3WQ9	CHLE_HUMAN	Gene/Protein Processing	[3]

References

• [1] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [2] Scintillation proximity assay for measuring uptake by the human drug transporters hOCT1, hOAT3, and hOATP1B1. Anal Biochem. 2007 Jul 15;366(2):117-25.
• [3] The mechanism and benefit of human butyrylcholinesterase activation by what would otherwise be inhibitors. Chem Biol Interact. 2019 Aug 1;308:350-356.
• [4] Identification of novel inhibitors of UDP-Glc 4'-epimerase, a validated drug target for african sleeping sickness. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5744-7.
• [5] Crystal structure of beta1,4-galactosyltransferase complex with UDP-Gal reveals an oligosaccharide acceptor binding site. J Mol Biol. 2002 Apr 26;318(2):491-502.
• [6] DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
• [7] Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
• [8] Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
• [9] Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
• [10] Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
• [11] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [12] Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
• [13] Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
• [14] Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
• [15] Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
• [16] Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
• [17] Increased organophosphate scavenging in a butyrylcholinesterase mutant. Chem Biol Interact. 2008 Sep 25;175(1-3):376-9. doi: 10.1016/j.cbi.2008.04.012. Epub 2008 Apr 22.
• [18] Comparative effects of cationic triarylmethane, phenoxazine and phenothiazine dyes on horse serum butyrylcholinesterase. Arch Biochem Biophys. 2008 Oct 15;478(2):201-5.
• [19] Lichens of parmelioid clade as promising multitarget neuroprotective agents. Chem Res Toxicol. 2019 Jun 17;32(6):1165-1177.
• [20] Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain. Acta Biol Hung. 2003;54(2):183-9. doi: 10.1556/ABiol.54.2003.2.7.
• [21] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [22] Response of the newborn to succinlycholine injection in homozygotic atypical mothers. Anesthesiology. 1975 Jul;43(1):115-6. doi: 10.1097/00000542-197507000-00028.
• [23] Cholinesterase inhibition by phenothiazine and nonphenothiazine antihistaminics: analysis of its postulated role in synergizing organophosphate toxicity. Toxicol Appl Pharmacol. 1975 Feb;31(2):179-90.
• [24] Qualitative defects of pseudocholinesterase activity. Anaesthesia. 1967 Jan;22(1):55-68.